Shares of Oculis Holding AG (NASDAQ:OCS – Get Free Report) have received an average rating of “Moderate Buy” from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $38.3333.
A number of analysts recently weighed in on OCS shares. Robert W. Baird decreased their target price on shares of Oculis from $49.00 to $38.00 and set an “outperform” rating on the stock in a report on Monday, June 1st. Wall Street Zen lowered shares of Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. JPMorgan Chase & Co. decreased their target price on shares of Oculis from $42.00 to $23.00 and set an “overweight” rating on the stock in a report on Wednesday, June 3rd. Needham & Company LLC decreased their target price on shares of Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a report on Monday, June 1st. Finally, Guggenheim cut their price target on shares of Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a research note on Monday, June 1st.
Check Out Our Latest Research Report on Oculis
Hedge Funds Weigh In On Oculis
Oculis Stock Performance
Oculis stock opened at $10.98 on Wednesday. The firm’s 50 day simple moving average is $25.89 and its 200 day simple moving average is $24.86. The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $636.62 million, a PE ratio of -5.15 and a beta of 0.23. Oculis has a 1-year low of $10.52 and a 1-year high of $34.47.
Oculis (NASDAQ:OCS – Get Free Report) last posted its earnings results on Friday, May 8th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The firm had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. As a group, analysts expect that Oculis will post -2.27 earnings per share for the current fiscal year.
About Oculis
Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.
Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.
See Also
- Five stocks we like better than Oculis
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
